Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Kentuckiana Cancer Institute
RAndomized pilot study of supplemental Iscar in combination with Gemcitabine vs. Gemcitabine alone as second line treatment for advanced non-small cell lung cancer.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
newly diagnosed IIIB and IV NSCLC who have failed one prior line of chemo
Karnofsky score 60% or greater
patients who will be treated with Gemcitabine
Clareo Health | Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer
